Wegovy Cost in 2026: Pricing and Coverage Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

From the PlexusDx Education Hub: clear context on GLP-1 pricing, weight-management protocols, and the genetics that shape metabolic response. Browse every Peptides & GLP-1 guide.

Wegovy is positioned squarely as a weight-management product, and its cost question carries a particular weight because weight indications are exactly where insurance coverage tends to be least predictable. Understanding the price means understanding not just the sticker figure but the coverage rules that most affect a weight-focused prescription. This page lays out both, from list price down to what a patient may actually pay.

The 2026 list price

Wegovy's U.S. list price is approximately $1,349 per month as of April 2026, per Novo Nordisk published pricing. That is the highest list figure among the products commonly compared in this category, and, as with the others, it is a pre-insurance benchmark rather than a typical counter price. Rebates, savings cards, and pharmacy pricing all sit between it and the final bill.

Why weight indications complicate coverage

Commercial coverage depends on the FDA-approved indication on the prescription and the plan's formulary and prior authorization rules. Because Wegovy is a weight-management product, it runs directly into the area where coverage is most variable: many plans apply BMI-based prior authorization, and some exclude weight indications entirely. Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, though cardiovascular-indication coverage exists for some products.

Savings cards and coupons

Novo Nordisk publishes a manufacturer savings card that can substantially reduce monthly out-of-pocket cost for eligible commercially insured patients, with the usual exclusions for Medicare, Medicaid, TRICARE, and other government coverage, and monthly and annual caps. GoodRx, SingleCare, and similar platforms list coupon prices that vary by pharmacy. Confirm all terms at the time of fill, since they change frequently.

What patients actually pay

With commercial insurance that covers the indication and a savings card applied, eligible patients may pay as little as $25 per month, subject to plan terms and caps. Where a plan excludes the weight indication, cash-pay cost approaches list price minus any coupon. Uninsured cost sits near list price, while compounded options through PlexusDx Weight Management Protocols follow separate published pricing.

Compounded alternatives in context

During the FDA-declared shortages, 503A pharmacies legally compounded semaglutide and tirzepatide. The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, narrowing the window without ending legitimate compounding. Compounded semaglutide and tirzepatide remain available through licensed pathways where justified, and they are not identical to brand products and carry separate pricing.

Genetics behind weight biology

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, including Semaglutide Injection and Tirzepatide Injection. Before any spend, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R variants that shape appetite and energy balance. It does not predict medication response; it anchors the decision in your biology. See also Wegovy savings options and Wegovy side effects.

Planning around the highest list price in the category

Because Wegovy carries the highest list price among the products commonly compared here, the gap between its sticker figure and what a covered patient actually pays can be especially dramatic. That makes the coverage questions more consequential, not less. A plan that includes the weight indication and an applied savings card can shrink a large list number substantially, while a plan that excludes weight coverage leaves far more exposure to absorb. Anyone budgeting for Wegovy benefits from confirming, in advance, whether their plan recognizes the weight-management indication, what its prior authorization requires, and how the savings-card monthly and annual caps behave across a full year. Deductible timing can shift the figure too, particularly early in a plan year. Those answers matter far more to the real cost than the headline number, which few insured patients ever pay in full. Treating the list price as a ceiling to work down from, rather than a bill to expect, keeps your planning grounded in how coverage actually operates.

Frequently Asked Questions

How much does Wegovy cost per month?

The U.S. list price is approximately $1,349 per month as of April 2026, per Novo Nordisk published pricing. Insurance, savings cards, and pharmacy pricing can change that figure substantially at the counter, so verify the current price with your pharmacy before filling any prescription.

Does insurance cover Wegovy for weight loss?

It depends on the plan, its formulary, the FDA indication, and prior authorization criteria. Weight-management coverage is the most variable category; many plans use BMI-based prior authorization and some exclude it. Medicare does not cover weight-management indications for weight alone as of April 2026.

Can a savings card reduce the cost?

Novo Nordisk publishes a manufacturer savings card for eligible commercially insured patients that can bring monthly cost to as little as $25 under some plans. Government-insurance patients are generally excluded, and terms and caps change, so check the manufacturer site when the prescription is filled.

Are there lower-cost alternatives to Wegovy?

Compounded semaglutide is priced separately from brand Wegovy, but it is legally and factually different, not a generic, and its quality varies by pharmacy. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, with per-protocol pricing published on each product page.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.